AbCellera Biologics Inc. announced that at its AGM held on June 13, 2024, the shareholders approved the election of Andrew Lo, Ph.D. as Class I directors of the company to serve for a three-year term expiring at the company?s annual meeting of shareholders in 2027 and until his or her successor has been elected and qualified.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.13 USD | +11.79% |
|
+15.50% | -45.18% |
Jul. 11 | KeyBanc Adjusts Price Target on AbCellera Biologics to $5 From $7, Maintains Overweight Rating | MT |
Jun. 13 | AbCellera Biologics Inc. Approves Election of Andrew Lo as Class I Director | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.18% | 823M | |
+23.50% | 45.01B | |
+47.19% | 40.96B | |
-5.16% | 38.62B | |
+36.37% | 32.6B | |
-7.79% | 27.49B | |
+18.06% | 27.17B | |
+47.29% | 14.61B | |
+41.91% | 12.95B | |
-1.02% | 11.36B |
- Stock Market
- Equities
- ABCL Stock
- News AbCellera Biologics Inc.
- AbCellera Biologics Inc. Approves Election of Andrew Lo as Class I Director